Import from '@/components/mdx'

Can I Take Ashwagandha With CJC-1295? A Women's Guide to This Combination

What CJC-1295 Actually Does in Your Body

CJC-1295 (also called modified GRF 1-29, or mod GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH). Its job is to stimulate your pituitary gland to release growth hormone (GH) in a pulsatile pattern that mirrors your body's natural overnight secretion. Longer-acting versions of CJC-1295 that include a drug affinity complex (DAC) extend that pulse by binding to albumin and slowing clearance.

In women, GH secretion is already substantially higher than in men. Research published in the Journal of Clinical Endocrinology and Metabolism found that young women secrete roughly twice as much GH per 24 hours as age-matched men, driven by estrogen's amplifying effect on pituitary somatotrophs. This matters because the baseline you're starting from is different.

How Estrogen Changes Your GH Response

Estrogen directly upregulates GHRH receptor sensitivity. During the follicular phase of your cycle, when estrogen peaks, GH pulse amplitude is at its highest. After menopause, falling estrogen causes GH secretion to drop significantly. One study in the Journal of Clinical Endocrinology and Metabolism showed that postmenopausal women on oral estrogen therapy had markedly higher GH levels than women on transdermal estrogen or no HRT, partly because oral estrogen's hepatic first-pass effect impairs IGF-1 production and removes the feedback brake on GH release.

If you are postmenopausal and taking oral estrogen, you may respond differently to CJC-1295 than a woman in her reproductive years. No clinical trial has examined this directly.

CJC-1295 in the 503A Compounding Context

CJC-1295 is not FDA-approved as a standalone drug. It is available through 503A compounding pharmacies when prescribed by a licensed clinician. The FDA's guidance on compounded peptides means its quality, purity, and potency vary by pharmacy. This is a meaningful safety consideration that is separate from any supplement interaction.

What Ashwagandha Does Hormonally

Ashwagandha (Withania somnifera) is an adaptogenic root extract whose primary active constituents are withanolides. It works on at least three hormonal axes that overlap directly with CJC-1295's targets.

The HPA Axis and Cortisol

Ashwagandha's best-documented effect is cortisol reduction via HPA axis modulation. A double-blind, randomized controlled trial in Medicine (2019) of 60 stressed adults found that 240 mg daily of a standardized ashwagandha extract (KSM-66) reduced serum cortisol by 23% at 60 days compared to placebo. This is a pharmacodynamically significant reduction.

Cortisol is not just a stress hormone. It directly inhibits GHRH release from the hypothalamus. When cortisol drops, the brake on GH pulsatility loosens. Combining an agent that raises GH (CJC-1295) with one that removes a cortisol-mediated brake on GH (ashwagandha) creates a theoretically additive GH-stimulating effect. Whether this produces a clinically meaningful overshoot in IGF-1 has not been tested in any published human trial.

Testosterone and LH Effects in Women

A placebo-controlled trial in BioMed Research International found that ashwagandha supplementation in reproductively healthy men raised testosterone by roughly 17% and LH by 34%. The picture in women is less clear. A small 2015 study in the Journal of the International Society of Sports Nutrition showed improvements in muscle recovery and hormonal markers in women taking ashwagandha, but testosterone was not a primary endpoint.

For women with PCOS, who already have elevated LH and often elevated androgens, any supplement that further raises LH or free testosterone carries a specific flag that does not apply to the average male subject in a trial. This is an area where the evidence gap is real and matters for your decision.

Thyroid Effects

Ashwagandha has demonstrated thyroid-stimulating activity in animal models and in at least one small human study. A pilot randomized trial in the Journal of Alternative and Complementary Medicine showed that 600 mg daily of ashwagandha root extract significantly increased serum T3 and T4 in subclinically hypothyroid adults over 8 weeks. CJC-1295 and the GH/IGF-1 axis also interact with thyroid function: elevated IGF-1 can modulate deiodinase activity and change T3 production.

Running both compounds simultaneously means two inputs affecting thyroid output. Women are five to eight times more likely than men to have thyroid disease. The American Thyroid Association estimates that one in eight women will develop a thyroid condition during her lifetime. If you have Hashimoto's thyroiditis, hypothyroidism, or postpartum thyroiditis, this dual thyroid stimulation deserves close monitoring.

Understanding the Interaction: Pharmacokinetic or Pharmacodynamic?

The CJC-1295 and ashwagandha interaction is pharmacodynamic, not pharmacokinetic.

CJC-1295 is a peptide. It is broken down by peptidases in the bloodstream and tissues, not by CYP450 liver enzymes. Ashwagandha's withanolides are metabolized hepatically, but they do not appear to be major CYP3A4 or CYP2D6 modulators at standard doses. So the two compounds are not competing for the same metabolic pathways. They are, instead, tugging on the same hormonal levers from different ends.

Here is a practical framework for thinking about this combination across three overlapping axes:

| Axis | CJC-1295 effect | Ashwagandha effect | Combined signal | |---|---|---|---| | GH/IGF-1 | Raises GH pulse amplitude | Lowers cortisol, removing one GH brake | Possibly additive GH/IGF-1 rise | | HPA / Cortisol | GH itself slightly suppresses cortisol | Directly reduces serum cortisol | Potentially greater cortisol reduction | | Thyroid (T3/T4) | Elevated IGF-1 may modulate deiodinase | Raises T3 and T4 in hypothyroid subjects | Unpredictable if thyroid disease present | | LH / Androgens | GH can potentiate LH sensitivity | May raise LH and testosterone | PCOS risk flag |

No published clinical trial has directly tested this combination in humans of any sex.

How Your Life Stage Changes This Equation

Reproductive-Age Women (Typically Ages 18 to 40)

If your cycles are regular and you are not pregnant or trying to conceive, the interaction is most relevant if you have PCOS. PCOS already features elevated LH pulses, high androgens, and often elevated IGF-1. Layering a GH secretagogue on top of ashwagandha-mediated LH elevation could worsen androgen excess and affect ovulation. Discuss this with your prescriber before starting.

Women using CJC-1295 for body composition should also know that IGF-1 reference ranges differ by sex, with women generally having slightly lower age-matched IGF-1 targets. Chasing IGF-1 levels based on male norms may result in supraphysiologic values.

Trying to Conceive

Neither compound has been tested for safety in women trying to conceive. CJC-1295 has no human reproductive safety data. Ashwagandha has demonstrated uterotonic activity in animal studies. Stop both at least one full menstrual cycle before active conception attempts, and consult a reproductive endocrinologist.

Perimenopausal Women (Typically Ages 40 to 55)

This is arguably the life stage where the combination has the most hypothetical appeal and the most hormonal complexity. GH secretion declines with age, cortisol dysregulation is common, and thyroid disease prevalence rises. CJC-1295 is sometimes prescribed off-label for age-related GH decline. Ashwagandha is used for sleep, stress, and cognitive fog, all common perimenopause complaints.

The overlap of thyroid stimulation from ashwagandha with rising Hashimoto's risk in perimenopause makes TSH monitoring non-negotiable if you take both. A perimenopausal woman on thyroid medication should not add ashwagandha without her clinician's sign-off.

Postmenopausal Women

As described above, GH secretion drops after menopause, and the estrogen-driven amplification of GHRH sensitivity is lost. CJC-1295 may produce a larger relative GH lift in this group, though head-to-head data comparing pre and postmenopausal response does not exist. Bone metabolism is also relevant: GH and IGF-1 support bone remodeling. A 2014 analysis in Osteoporosis International found that low IGF-1 is independently associated with increased fracture risk in postmenopausal women. Whether CJC-1295 translates to better bone outcomes in this group is not established.

Pregnancy and Lactation: A Clear Warning

CJC-1295 is not safe during pregnancy or breastfeeding. This is not a gray area.

CJC-1295 has no pregnancy category under the old FDA classification system and has received no pregnancy safety assessment under the current pregnancy and lactation labeling rule (PLLR). There are no human data. Animal reproductive toxicity studies have not been conducted and published for this compound. The default for any untested GH-axis-active peptide in pregnancy is avoidance.

During pregnancy, GH secretion from the maternal pituitary is progressively suppressed by placental GH, which takes over the role of driving IGF-1. Introducing an exogenous GHRH analogue into this tightly regulated system carries unknown risk to placental function and fetal growth.

Ashwagandha is similarly contraindicated in pregnancy. Traditional Ayurvedic medicine has used ashwagandha as an abortifacient, and animal studies demonstrate uterotonic and abortifacient effects at higher doses. No clinical safety data in pregnant women exist.

If you are pregnant, planning pregnancy within 3 months, or breastfeeding, stop both compounds and discuss alternative options with your OB-GYN or midwife. Contraception is not formally required in prescribing guidelines for CJC-1295 as it is for some teratogens, but the absence of safety data makes reliable contraception a reasonable clinical expectation for any woman of reproductive age using this peptide.

Lactation transfer of CJC-1295 has not been studied. Peptides can theoretically be expressed in breast milk. Ashwagandha's withanolides may also transfer; the impact on a nursing infant is unknown.

Who This Combination May Be Appropriate For (and Who Should Avoid It)

Potentially Appropriate, With Clinical Supervision

• Postmenopausal women with confirmed GH deficiency on a stable treatment plan, adding low-dose ashwagandha for stress or sleep under clinician monitoring with regular IGF-1 and TSH checks.
• Perimenopausal women without thyroid disease, working with a prescriber who reviews labs every 8 to 12 weeks.
• Reproductive-age women without PCOS, not pregnant or trying to conceive, using evidence-based doses of both compounds.

Avoid or Use Only With Specialist Oversight

• Women with PCOS (androgen and LH interaction concern).
• Women with any thyroid condition, including Hashimoto's, Graves, or those on levothyroxine or methimazole (dual thyroid stimulation).
• Women who are pregnant, breastfeeding, or actively trying to conceive.
• Women with a history of hormone-sensitive cancers (the IGF-1-raising effect of CJC-1295 raises theoretical concern, though causality is not established).
• Women with insulin resistance or prediabetes: GH raises blood glucose acutely by inducing insulin resistance. A study in Diabetes Care documented that GH administration worsens insulin sensitivity in a dose-dependent manner. Add this to PCOS-related insulin resistance and you may see fasting glucose worsen.

Dosing, Timing, and Practical Monitoring

No specific dose-separation window between CJC-1295 and ashwagandha is required, because the interaction is pharmacodynamic rather than pharmacokinetic. You do not need to time them hours apart for absorption reasons. The concern is the cumulative hormonal effect over days to weeks, not a single-dose peak interaction.

If you are already taking both:

1. Get baseline labs before continuing: IGF-1 (sex and age-matched reference range), fasting glucose, TSH, free T3, morning cortisol, and for women with PCOS, free testosterone and LH.
2. Recheck at 8 weeks and 16 weeks.
3. If IGF-1 rises above the upper limit of the age- and sex-adjusted range, discuss reducing CJC-1295 dose or frequency with your prescriber.
4. If TSH drops below 0.5 mIU/L or rises above 4.0 mIU/L, hold ashwagandha and recheck in 6 weeks.
5. Track fasting glucose. A rise above 100 mg/dL from a normal baseline warrants a conversation with your provider.

Standard CJC-1295 without DAC is typically dosed at 100 to 200 mcg subcutaneously before sleep, 5 days on and 2 days off, through a 503A pharmacy. Ashwagandha doses used in clinical trials range from 240 mg of a standardized KSM-66 extract to 600 mg of root extract daily. Higher doses carry greater cortisol-reduction and potential thyroid-stimulating effects.

The Evidence Gap: What We Do Not Know and Why It Matters

Women have been systematically under-represented in trials of both GH secretagogues and adaptogenic supplements. The cortisol-reduction studies on ashwagandha used mostly male or mixed cohorts without stratifying by menstrual cycle phase, menopausal status, or hormonal contraceptive use. The NIH Office of Research on Women's Health has documented this gap repeatedly, and it applies squarely here.

The testosterone-raising effect of ashwagandha comes almost entirely from male subjects. Whether it raises androgens in women, and whether that effect differs across the menstrual cycle or with OCP use, is essentially unstudied.

The same gap exists for CJC-1295: the published human studies are small, often in male-predominant cohorts, and do not include subgroup analyses by sex, cycle phase, or menopausal status. A 2006 study in the Journal of Clinical Endocrinology and Metabolism examined CJC-1295 pharmacokinetics in 21 healthy adults, but the sex breakdown was not reported in a way that allows women-specific conclusions.

Honest clinical guidance requires naming these gaps, not papering over them.

Clinician Perspective

Maya Okafor, MD, reviewing clinician for this article, notes: "The appeal of combining a GH secretagogue with an adaptogen is understandable, particularly for perimenopausal patients dealing with fatigue, body composition changes, and poor sleep simultaneously. What I want patients to understand is that the hormonal axes involved here, GH, cortisol, thyroid, and androgens, do not operate independently in women the way they tend to be described in supplement marketing. Before I sign off on this combination for any patient, I want at minimum an IGF-1, TSH, fasting glucose, and if PCOS is in the picture, a free testosterone. The absence of interaction data is not reassurance. It means we watch more carefully."